» Articles » PMID: 11756060

Elevated Plasma 4-pyridoxic Acid in Renal Insufficiency

Abstract

Background: Renal insufficiency is associated with altered vitamin B-6 metabolism. We have observed high concentrations of 4-pyridoxic acid, the major catabolite of vitamin B-6 metabolism, in plasma during renal insufficiency.

Objective: The objective was to evaluate the renal handling of 4-pyridoxic acid and the effects of renal dysfunction on vitamin B-6 metabolism.

Design: We measured the renal clearance of 4-pyridoxic acid and creatinine in 17 nonpregnant, 17 pregnant, and 16 lactating women. We then examined the influence of vitamin B-6 or alkaline phosphatase activity on the ratio of 4-pyridoxic acid to pyridoxal (PA:PL) in plasma in 10 men receiving a low (0.4 mg pyridoxine.HCl/d) or high (200 mg pyridoxine.HCl/d) vitamin B-6 intake for 6 wk, in 10 healthy subjects during a 21-d fast, in 1235 plasma samples from 799 people screened for hypophosphatasia, and in 67 subjects with a range of serum creatinine concentrations.

Results: Renal clearance of 4-pyridoxic acid was 232 +/- 94 mL/min in nonpregnant women, 337 +/- 140 mL/min in pregnant women, and 215 +/- 103 mL/min in lactating healthy women. These values were approximately twice the creatinine clearance, indicating that 4-pyridoxic acid is at least partially eliminated by tubular secretion. Elevated plasma creatinine concentrations were associated with marked elevations in 4-pyridoxic acid and PA:PL. PA:PL was not affected by wide variations in vitamin B-6 intake or by the wide range of pyridoxal-P concentrations encountered while screening for hypophosphatasia.

Conclusions: Plasma 4-pyridoxic acid concentrations are markedly elevated in renal insufficiency. Plasma PA:PL can distinguish between increases in 4-pyridoxic acid concentrations due to increased dietary intake and those due to renal insufficiency.

Citing Articles

Integration of bile proteomics and metabolomics analyses reveals novel insights into different types of gallstones in a high-altitude area.

Jing X, Ma Y, Li D, Zhang T, Xiang H, Xu F BMC Gastroenterol. 2024; 24(1):330.

PMID: 39350090 PMC: 11440720. DOI: 10.1186/s12876-024-03422-5.


Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug-Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective.

Choi H, Madari S, Huang F Clin Pharmacokinet. 2024; 63(6):735-749.

PMID: 38867094 PMC: 11222257. DOI: 10.1007/s40262-024-01385-0.


Intrauterine Growth Restriction Affects Colonic Barrier Function Regulating the Nrf2/Keap1 and TLR4-NF-κB/ERK Pathways and Altering Colonic Microbiome and Metabolome Homeostasis in Growing-Finishing Pigs.

Xiong L, Azad M, Liu Y, Zhang W, Zhu Q, Hu C Antioxidants (Basel). 2024; 13(3).

PMID: 38539817 PMC: 10967500. DOI: 10.3390/antiox13030283.


Effect of probenecid on blood levels and renal elimination of furosemide and endogenous compounds in rats: Discovery of putative organic anion transporter biomarkers.

Thakur A, Mettu V, Singh D, Prasad B Biochem Pharmacol. 2023; 218:115867.

PMID: 37866801 PMC: 10900896. DOI: 10.1016/j.bcp.2023.115867.


Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.

Huh Y, Plotka A, Wei H, Kaplan J, Raha N, Towner J Pharm Res. 2023; 40(11):2639-2651.

PMID: 37561322 PMC: 10733197. DOI: 10.1007/s11095-023-03564-3.